More from the Author

• Supplement | HBS Case Collection | April 2018

  Celgene

  Malcolm Baker and Emily R. McComb

  In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene’s key drug, Revlimid. In response, Celgene’s share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial investment.

  Keywords: life sciences; biotechnology; public market investing; Celgene; Revlimid; hedge fund; valuation; growth stocks; Valuation; Investment; Decision Choices and Conditions; Analysis;

  Citation:

  Baker, Malcolm, and Emily R. McComb. "Celgene." Harvard Business School Spreadsheet Supplement 218-743, April 2018.  View Details

  CiteView DetailsPurchase

  Related

• Case | HBS Case Collection | March 2018

  Celgene

  Malcolm Baker and Emily McComb

  In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene’s key drug, Revlimid. In response, Celgene’s share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial investment.

  Keywords: life sciences; biotechnology; public market investing; Celgene; Revlimid; hedge fund; valuation; growth stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry;

  Citation:

  Baker, Malcolm, and Emily McComb. "Celgene." Harvard Business School Case 218-094, March 2018.  View Details

  CiteView DetailsEducators

  Related

• Supplement | HBS Case Collection | March 2018

  Celgene (B)

  Malcolm Baker and Emily McComb

  In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene’s key drug, Revlimid. In response, Celgene’s share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial investment.

  Keywords: life sciences; biotechnology; public market investing; Celgene; Revlimid; hedge fund; valuation; growth stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry;

  Citation:

  Baker, Malcolm, and Emily McComb. "Celgene (B)." Harvard Business School Supplement 218-099, March 2018.  View Details

  CiteView Details

  Related